Linnebur Sunny A, Parnes Bennett L
Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262-0238, USA.
Ann Pharmacother. 2004 Apr;38(4):612-6. doi: 10.1345/aph.1D306. Epub 2004 Feb 13.
To reemphasize potential risks associated with chronic nitrofurantoin use and to report a case of combined pulmonary and hepatic toxicity precipitated from acute use of fluconazole concomitantly with chronic nitrofurantoin.
A 73-year-old white man taking nitrofurantoin 50 mg/day for 5 years developed combined hepatic and pulmonary toxicity after taking fluconazole acutely for onychomycosis. Two months after starting fluconazole, the patient's hepatic enzymes showed elevation 5 times the upper limits of normal. In addition, the patient reported fatigue, dyspnea on exertion, pleuritic pain, burning trachea pain, and a cough. Chest X-rays showed bilateral pulmonary disease consistent with nitrofurantoin toxicity. Both drugs were determined to be the cause of the patient's pulmonary and hepatic toxicity, so they were discontinued. Pulmonary function tests measured after discontinuation were abnormal and also consistent with nitrofurantoin toxicity. The patient's hepatic and pulmonary toxicity resolved upon discontinuation of both drugs and use of inhaled corticosteroids.
Changes in hepatic enzyme measurement, pulmonary function measurements, and chest X-rays indicate that our patient developed hepatic and pulmonary toxicity due to his drug therapy. An objective causality assessment revealed that these adverse events were probably due to fluconazole given with nitrofurantoin. Either drug may have caused the hepatic toxicity. However, it is possible that pharmacokinetic changes induced by an interaction with fluconazole precipitated the nitrofurantoin-induced pulmonary toxicity.
Our patient developed pulmonary and hepatic toxicity after starting fluconazole in combination with chronic nitrofurantoin. A potential drug interaction of unknown mechanism may have been the cause of the toxicities.
再次强调长期使用呋喃妥因的潜在风险,并报告一例因急性使用氟康唑并同时长期使用呋喃妥因而引发的肺和肝联合毒性病例。
一名73岁白人男性,服用50毫克/天呋喃妥因达5年,在因甲癣急性服用氟康唑后出现肝和肺联合毒性。开始服用氟康唑两个月后,患者的肝酶升高至正常上限的5倍。此外,患者自述疲劳、劳力性呼吸困难、胸膜炎性疼痛、气管灼痛和咳嗽。胸部X光显示双侧肺部疾病,符合呋喃妥因毒性表现。确定两种药物均为患者肺和肝毒性的病因,遂停用。停药后进行的肺功能测试结果异常,也符合呋喃妥因毒性表现。停用两种药物并使用吸入性糖皮质激素后,患者的肝和肺毒性得以缓解。
肝酶测量、肺功能测量和胸部X光的变化表明,我们的患者因药物治疗出现了肝和肺毒性。客观的因果关系评估显示,这些不良事件可能是由于氟康唑与呋喃妥因联用所致。两种药物都可能导致肝毒性。然而,与氟康唑相互作用引起的药代动力学变化可能引发了呋喃妥因所致的肺毒性。
我们的患者在开始联合使用氟康唑和长期使用呋喃妥因后出现了肺和肝毒性。一种机制不明的潜在药物相互作用可能是毒性的原因。